Skin Cancer

Cosibelimab joins cemiplimab and pembrolizumab as a first-line option for advanced cSCC unsuitable for curative surgery or radiation.

Because BCC and cSCC have high tumor mutational burdens driven by UV-induced DNA damage, they are particularly well suited to immune checkpoint inhibition.

The June issue of Dermatology Times highlights the latest advances in skin cancer, psoriasis, atopic dermatitis, hidradenitis suppurativa, and emerging dermatology technologies.

At 6-month follow-up, no behavioral outcomes — including sunscreen use, hat use, or reapplication — showed statistically significant improvement over baseline levels.

Learn how community events, like the recent Walk Under the Sun event, help turn sunscreen into a daily habit, explain hidden UV exposure, and debunk viral tanning myths.

The proposed rule, first introduced in 2015, aimed to prohibit indoor tanning for individuals under 18 because of the known cancer risks associated with UV radiation.

Neal Bhatia, MD, explains why photodynamic therapy's ability to target subclinical damage across the entire field makes it one of dermatology's most powerful chemopreventive tools.

Kavita Mariwalla, MD, FAAD, explains why melanoma is rising in young women, how tanning trends and sunscreen myths spread online, and what prevention steps work best in younger patients.

Clinicians discuss how melanoma gene expression profiling guides sentinel node biopsy choices, refines early-stage risk, and shapes personalized surveillance and oncology referral.

Neal Bhatia, MD, makes the case for photodynamic therapy as a versatile, field-treating option, not just an alternative to surgery.

Australian multicenter data shows older head and neck squamous cell carcinoma patients often miss standard radiotherapy-plus-chemo, yet guideline care boosts survival.

A phase 1/2 trial enrolling patients with refractory melanoma is now actively recruiting.

The high-dose D-MNA cohort showed continued improvement from Day 29 to Day 57, a trajectory not observed in the device-only control arm, supporting a drug-driven mechanism of action.

Daniel Condie, MD, shares kid-friendly sun safety tips, tanning bed warnings, and early skin cancer detection advice that clinicians can share with families and teens.

MRA commits a record $18.4M to global melanoma research, boosting rare-subtype collaboration, biorepositories, biomarkers, and next-gen therapies to combat rising cases.

Daniel Condie, MD, debunks common Gen Z tanning myths, warns base tans and sunscreen fears fuel early skin cancer, and explains Mohs care challenges.

As Melanoma Monday kicks off May's Skin Cancer Awareness Month, we're spotlighting the latest emerging data, evolving tools, and public health initiatives for clinicians.

Medicus seeks FDA orphan drug status for SkinJect, a dissolvable microneedle doxorubicin patch targeting Gorlin-related basal cell carcinomas, aiming to reduce the need for repeated surgery.

Many participants in the mobile screening program have never previously seen a dermatologist.

New studies suggest tattoo pigments migrate to lymph nodes, complicate skin exams, and may raise lymphoma risk—what dermatologists now watch for.

The newly published tool, ODD-SPOT, offers a plain-language, photo-supported alternative to the ABCDE criteria, designed to capture the key warning signs of BCC, SCC, and melanoma in accessible terms.

At AAD 2026, Todd Schlesinger, MD, highlighted how staging frameworks and clinicopathologic features can inform treatment decisions in nonmelanoma skin cancer.

New sunscreen filters, AI tools, and immunotherapies are reshaping skin cancer prevention and treatment, improving precision and long-term survival.

During the late-breaking research session at the 2026 AAD Annual Meeting 2026, Mary Spellman, MD, shared successful news about intratumoral PH762 for cutaneous carcinomas.